Getting a GLP-1 covered: the denial taxonomy and the appeal that answers it
Insurance denials feel like verdicts. Most are checklists with a missing item. The difference between the two is the denial code on page one.
GLP-1 denials fall into five buckets: benefit exclusion (weight-loss drugs not covered — rarely appealable), missing prior-authorization documentation (highly winnable), step-therapy requirements (winnable with history), off-formulary drug (winnable via exception when the preferred drug failed), and BMI/criteria mismatch (winnable when charting was incomplete). Read the denial letter's stated reason first — the entire strategy follows from it, and appeal deadlines (typically 180 days internal, then external review) start at the letter date.
- Read the denial: Every denial letter states a reason, and the reason is the strategy.
- Winning the prior authorization the first time: Approvals turn on documentation density, not eloquence.
- Step therapy and formulary exceptions: Step therapy (“fail first”) requires documented trial of the plan's preferred option — typically the preferred GLP-1, sometimes older agents.
- The appeal ladder and its deadlines: Level one is the internal appeal — a written request with new documentation, typically due within 180 days of the denial, decided within 30 days fo....
- The letter of medical necessity: Effective letters are one to two pages with a fixed skeleton: patient identifiers and the specific drug/dose requested; diagnosis with codes and du....
Read the denial: the five reasons and their odds
Every denial letter states a reason, and the reason is the strategy. A benefit exclusion — “your plan does not cover medications for weight loss” — is a plan-design decision; no clinical letter overturns it, and your energy belongs in the indication route (diabetes, cardiovascular risk, sleep apnea) or cash-pay routes instead. Everything else is process, and process is winnable.
Missing-documentation denials are the most common and most mechanical: the PA asked for a BMI history, a comorbidity list, or prior-attempt documentation that never arrived. Step-therapy denials want a cheaper drug tried first. Formulary denials want you on the plan's preferred GLP-1. Criteria denials claim you miss the BMI or comorbidity threshold — frequently because the chart is thinner than the patient's actual history.
| Denial reason | Winnable? | The move |
|---|---|---|
| Benefit exclusion | Rarely | Indication route or cash-pay; change plans at enrollment |
| Missing documentation | Highly | Cure the chart; resubmit or appeal with records |
| Step therapy | Usually | Document preferred-drug trial/intolerance per plan wording |
| Off-formulary | Often | Exception letter citing failure + head-to-head evidence |
| Criteria mismatch | Often | Consolidate BMI/comorbidity history into the chart |
Winning the prior authorization the first time
Approvals turn on documentation density, not eloquence. The winning packet contains: current BMI plus a dated BMI history establishing chronicity; the diagnosis codes for every weight-related condition (hypertension, dyslipidemia, prediabetes or T2D, OSA with the sleep study, NAFLD); a dated record of prior weight-loss attempts — programs, medications, outcomes; and the prescriber's specific dosing plan.
The most common self-inflicted wound is the thin chart: years of real comorbidities that were managed but never coded into the record the PA reviewer sees. Fifteen minutes with your clinician consolidating that history into the chart before submission does more than any appeal afterward. If the OSA route applies — Zepbound's separate indication — a sleep study transforms the entire application.
Step therapy and formulary exceptions
Step therapy (“fail first”) requires documented trial of the plan's preferred option — typically the preferred GLP-1, sometimes older agents. The keys are in your plan's own criteria document: the exact trial duration it requires and its stated definition of failure or intolerance. Match your documentation to those words. Documented adverse effects (intractable GI symptoms, injection-site reactions) qualify as intolerance and shortcut the duration requirement on most plans.
Formulary exceptions follow the same grammar: the letter shows the preferred drug was tried and failed by the plan's definition, or is contraindicated, and cites the clinical basis for the requested drug — SURMOUNT-5's head-to-head superiority is legitimate citable evidence when requesting tirzepatide after semaglutide failure. From October 2026, CVS Caremark's dual-preferred tier removes this fight for the largest commercial population.
The appeal ladder and its deadlines
Level one is the internal appeal — a written request with new documentation, typically due within 180 days of the denial, decided within 30 days for future care (72 hours if expedited for urgent situations). It is reviewed by the plan, but by different eyes, and documentation-cure appeals succeed at high rates. Level two, where offered, is a second internal review.
After internal exhaustion, federal law gives most commercial members an external review by an independent review organization whose decision binds the plan. External reviewers apply medical evidence, not plan preference — which is where trial citations and specialty-society guidance carry most weight. Medicare and Medicaid run parallel appeal ladders with their own deadlines; the denial letter is required to state yours.
The letter of medical necessity: structure that works
Effective letters are one to two pages with a fixed skeleton: patient identifiers and the specific drug/dose requested; diagnosis with codes and duration; the objective record (BMI trajectory, labs, sleep study, blood pressure); prior attempts and their documented outcomes; the clinical rationale citing trial evidence for this drug in this patient; and the risk statement — what untreated obesity plus these comorbidities costs in expected outcomes.
Two credibility rules: every claim in the letter must trace to something in the chart, and the letter should quote the plan's own criteria language back to it, item by item, showing each one met. Appeals are read by reviewers scoring against a checklist; a letter organized as that checklist wins.
If the plan truly excludes it
When the answer is a hard benefit exclusion, the ranked fallbacks in 2026: the indication routes (Mounjaro under diabetes criteria, Wegovy under cardiovascular risk reduction with established CVD, Zepbound under OSA with a sleep study); Medicare's GLP-1 Bridge pilot for eligible Part D members; manufacturer self-pay channels at $199–$499; and verified compounded programs at $99–$259 with their standing non-FDA-approved caveats.
Open-enrollment season is the structural fix: plans differ sharply on GLP-1 coverage, and for a therapy costing thousands per year, coverage is worth weighing against premium differences when choosing next year's plan.
Frequently asked questions
What percentage of appeals succeed?
Published figures vary by plan and category, but internal appeals that cure a documentation gap succeed at materially high rates, and external reviews overturn a meaningful share of upheld denials. The constant across datasets: most denials are never appealed at all.
Can my telehealth provider handle the prior authorization?
Many do, and some (and some manufacturers' programs) offer coverage-check services. The chart still has to contain the history — no PA team can cite records that were never created.
Is it worth appealing a weight-loss benefit exclusion?
Usually no — exclusions are plan design, not clinical judgment. Redirect the effort to a covered indication you genuinely have, the Medicare Bridge pilot if eligible, or the cash-pay routes while you change plans at open enrollment.